CIK 0000727510
- Non-accelerated filer
- Smaller reporting company
Viskase Holdings, Inc.
Sign in to watch- Ticker
- VISK
- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 222372868
- Phone
- +1 630-874-0700
- Business address
- 333 EAST BUTTERFIELD ROAD, SUITE 400, LOMBARD, IL, 60148
- Former names
- ENZON PHARMACEUTICALS, INC., ENZON PHARMACEUTICALS INC, ENZON PHARMACEUTICALS INC, ENZON PHARMACEUTICAL INC, ENZON INC
- 4 Shares withheld for taxes COO and Princ. Exec. Officer gave up 11,546 shares (to pay taxes)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Shares withheld for taxes EVP, R&D, CSO gave up 1,063 shares (to pay taxes)
- 4 Shares withheld for taxes COO and Princ. Exec. Officer gave up 1,417 shares (to pay taxes)
- 4 Shares withheld for taxes Exec. Vice Pres. HR gave up 1,181 shares (to pay taxes)
- 4 Grant or award COO and Principal Exec Officer acquired 15,000 shares (grant or award)
- 4 Grant or award EVP, President of R&D and CSO acquired 15,000 shares (grant or award)
- 4 Grant or award Exec. Vice Pres. HR acquired 8,000 shares (grant or award)
- 4 Open-market sale EVP, R&D, CSO sold 258,900 shares at an average $10.67 ($2,762,992)
- 4 Shares withheld for taxes EVP, R&D, CSO gave up 7,084 shares (to pay taxes)
- 4 Open-market sale Director sold 10,000 shares at an average $10.49 ($104,929)
- 3 Insider Initial Statement of Ownership
- 4 Grant or award Director acquired 14,086 shares (grant or award)
- 4 Grant or award Director acquired 7,043 shares (grant or award)
Page 7 of 28 · 560 filings